Parkinson's Disease Clinical Trial
Official title:
Efficacy Investigation of a Non-invasive Wearable Electrostimulation Device for Alleviation of Parkinson's Disease Symptoms
Verified date | July 2017 |
Source | Koç University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Investigation efficacy of a non-invasive wearable electrostimulator device where the supplementary motor area, premotor area and/or subthalamic nucleus are stimulated bilaterally and extracranially.
Status | Completed |
Enrollment | 24 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of Parkinson's Disease - H&Y Stage >= 2 - Existing bradykinesia symptoms - Existence of one of the symptoms below - Resting Tremor - Rigidity - Walking disorder Exclusion Criteria: - Cardiac Pacemaker - Psychiatric diagnosis - Irregular heart/respiration rate - Pregnancy - Alcohol consumption - Cardiovascular disease history - Wearing an electro-active prosthesis - Brain surgery history - Ongoing TENS/PENS therapy |
Country | Name | City | State |
---|---|---|---|
Turkey | Istanbul University | Istanbul | |
Turkey | Koc University Hospital | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Koç University | Istanbul University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the UPDRS Motor Score (Part III) | Evaluation of patients' disease level with UPDRS examination at the middle of the stimulation | 10 minutes after the stimulation is initiated. | |
Primary | Change in the UPDRS Motor Score (Part III) | Evaluation of patients' disease level with UPDRS examination 30 minutes after the stimulation is terminated. | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters (cadence) | cadence | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters (Stride length) | Stride length in meters | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters (Stride velocity) | Stride velocity in m/s | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Arm Swing Rate | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Arm Range of Motion | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Sit to Stand Duration | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Sit to Stand Peak Trunk Velocity | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Sit to Stand Peak Trunk Angle | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Leg Swing Rate | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Leg Range of Motion | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Turn to Sit Peak Turn Velocity | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Turn-to-Sit Trunk Range of Motion in Sagittal Plane | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Knee Range of Motion | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters | Trunk Joint Angles | 10 minutes after the stimulation is initiated. | |
Secondary | Change in the gait and balance parameters (cadence) | cadence | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters (Stride length) | Stride length in meters | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters (Stride velocity) | Stride velocity in m/s | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Arm Swing Rate | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Arm Range of Motion | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Sit to Stand Duration | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Sit to Stand Peak Trunk Velocity | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Sit to Stand Peak Trunk Angle | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Leg Swing Rate | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Leg Range of Motion | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Turn-to-Sit Peak Turn Velocity | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Turn-to-Sit Trunk Range of Motion | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Knee Range of Motion | 30 minutes after the stimulation is terminated. | |
Secondary | Change in the gait and balance parameters | Trunk Joint Angles | 30 minutes after the stimulation is terminated. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |